Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 1070861 | 4.6552 |
09:34 ET | 482040 | 4.6099 |
09:36 ET | 278434 | 4.68 |
09:38 ET | 287196 | 4.645 |
09:39 ET | 140142 | 4.665 |
09:41 ET | 385815 | 4.6501 |
09:43 ET | 258763 | 4.638 |
09:45 ET | 401328 | 4.6101 |
09:48 ET | 287229 | 4.69 |
09:50 ET | 228534 | 4.68 |
09:52 ET | 196228 | 4.651 |
09:54 ET | 170309 | 4.66 |
09:56 ET | 245233 | 4.665 |
09:57 ET | 196493 | 4.635 |
09:59 ET | 132095 | 4.66 |
10:01 ET | 183386 | 4.678 |
10:03 ET | 93651 | 4.675 |
10:06 ET | 161060 | 4.67 |
10:08 ET | 145434 | 4.63 |
10:10 ET | 235726 | 4.585 |
10:12 ET | 176671 | 4.585 |
10:14 ET | 113206 | 4.625 |
10:15 ET | 249691 | 4.645 |
10:17 ET | 210967 | 4.67 |
10:19 ET | 215915 | 4.72 |
10:21 ET | 954392 | 4.775 |
10:24 ET | 245403 | 4.805 |
10:26 ET | 278135 | 4.83 |
10:28 ET | 428555 | 4.855 |
10:30 ET | 179524 | 4.87 |
10:32 ET | 247355 | 4.8898 |
10:33 ET | 250176 | 4.8712 |
10:35 ET | 187109 | 4.8401 |
10:37 ET | 196756 | 4.9002 |
10:39 ET | 212279 | 4.9099 |
10:42 ET | 148044 | 4.89 |
10:44 ET | 222199 | 4.929 |
10:46 ET | 221602 | 4.921 |
10:48 ET | 296265 | 4.9113 |
10:50 ET | 230907 | 4.93 |
10:51 ET | 169218 | 4.9499 |
10:53 ET | 128184 | 4.925 |
10:55 ET | 108486 | 4.945 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.4B | -14.3x | --- |
CG Oncology Inc | 2.4B | -31.4x | --- |
Iovance Biotherapeutics Inc | 2.3B | -4.3x | --- |
Janux Therapeutics Inc | 2.4B | -34.8x | --- |
Vera Therapeutics Inc | 2.3B | -18.9x | --- |
Apogee Therapeutics Inc | 2.6B | -20.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | 4,562.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.